BIOHIT to launch the GastroPanel® Quick Test at BSG LIVE’23

June 19, 2023

BIOHIT is excited to launch its GastroPanel Quick Test at BSG LIVE’23, which will take place from the 19th to the 22nd of June at the Arena and Conference Centre (ACC) Liverpool. This annual meeting provides the ideal opportunity to share this innovation with colleagues in the gastroenterology and hepatology community, as they come together to discuss the latest advances in the field.

GastroPanel Quick Test is a revolutionary approach to the diagnosis of Helicobacter pylori infection, atrophic gastritis and high acid outputs in both symptomatic and asymptomatic patients. The rapid, non-invasive test investigates H. pylori infection and three stomach-specific biomarkers – pepsinogen I, pepsinogen II and gastrin-17 – in just 15 minutes. This can help clinicians to send patients for endoscopy sooner and at a fraction of the cost, promoting earlier cancer discovery and intervention through surveillance programmes.

Come and meet the BIOHIT team at stand B39 and be one of the first to witness the GastroPanel Quick Test in action. We hope to talk to as many visitors as possible, so make sure you book a personal meeting with us at We look forward to seeing you at this must-attend event of the year!

About BIOHIT HealthCare

BIOHIT HealthCare is a Finnish biotech company, headquartered in Helsinki, that specialises in the development, manufacture and distribution of kits and assays for the screening, diagnosis and monitoring of digestive diseases. Its core disease focus areas include stomach health and dyspepsia, reflux and acid dysregulation, Inflammatory Bowel Disease (IBD), functional gastrointestinal disorders (FGID), Irritable bowel syndrome (IBS), and gut microbiota dysbiosis. Innovating for Health

Recent Posts

Exploring the value of biomarkers in gastric cancer screening

October 26, 2023

Stomaching the lack of gastric cancer screening in Europe

October 18, 2023

Why is gastric cancer often diagnosed too late?

October 17, 2023

When should I test for BAD?

September 13, 2023